Concepedia

Author

Gordon T. McInnes

University of Glasgow

Also Known As

G MCINNES, G McInnes, G T McInnes, G. McInnes, G. T. McInnes, G.T. McINNES, G.T. McInnes, G.T. Mcinnes, GORDON McINNES, GORDON T. McINNES

193

Publications

19.5K

Citations

47

H-Index

100

Concepts

All Affiliations

University of GlasgowWestern InfirmaryImperial College LondonUniversity of MichiganIRCCS Istituto Auxologico Italiano
GT

About

Gordon T. McInnes is an author at University of Glasgow specializing in medicine, cardiovascular disease, and hypertension.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

22

33

13.2K

2

Public Health

13

15

9.1K

3

Health Sciences

2

2

154

4

Natural Sciences

2

2

50

5

Law

1

1

68

Gordon T. McInnes

×

73

Publications

18.6K

Citations

43

H-Index

YearCitations

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

Peter Sever, Björn Dahlöf, Neil R Poulter,

The Lancet

2003

3.8K

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

Björn Dahlöf, Peter Sever, Neil R Poulter,

The Lancet

2005

2.9K

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

Stevo Julius, Sverre E. Kjeldsen, Michael A. Weber,

The Lancet

2004

2.5K

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Bryan Williams, Thomas M. MacDonald, S. V. Morant,

The Lancet

2015

1.2K

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

Bryan Williams, Neil R Poulter, Morris J. Brown,

BMJ

2004

847

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

Michael A. Weber, Stevo Julius, Sverre E. Kjeldsen,

The Lancet

2004

591

Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

Anthony F. Lever, David Hole, C. Gillis,

The Lancet

1998

545

Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial???Lipid Lowering Arm (ASCOT-LLA)

Peter Sever, Bj rn Dahl f, Neil R Poulter,

Drugs

2004

521

Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes

Peter Sever, Neil R Poulter, Björn Dahlöf,

Diabetes Care

2005

392

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)

Neil R Poulter, Hans Wedel, Björn Dahlöf,

The Lancet

2005

317

Page 1